US drug company Lilly refuses to list Mounjaro on Australia’s nationally bargained drug scheme (PBS), says price too low. The Trump admin has repeatedly threatened to place tariffs on Australian medicines companies amid complaints from US manufacturers that the scheme is harming their profits.
Australians will still be able to buy Mounjaro outside the scheme but would have to pay full (American-like?) market price.
This is relevant because it concerns tensions between Australia’s collectivised bargaining system for drugs subsidised by the government, against the profit interests of US pharmaceutical companies, and potential intervention by the US administration through tarrifs to protect the interests of US companies. I expect r/neoliberal to find many parts of this story interesting as it relates to both trade, tarrifs, and national bargaining.
Unterfahrt on
For anyone who does a bit of research, you can buy gray-market GLP-1 agonists online that are better than mounjaro and ozempic. It’s not even that hard. This sort of price squeezing doesn’t work when the recipe is out there for all to see.
3 Comments
This is relevant because it concerns tensions between Australia’s collectivised bargaining system for drugs subsidised by the government, against the profit interests of US pharmaceutical companies, and potential intervention by the US administration through tarrifs to protect the interests of US companies. I expect r/neoliberal to find many parts of this story interesting as it relates to both trade, tarrifs, and national bargaining.
For anyone who does a bit of research, you can buy gray-market GLP-1 agonists online that are better than mounjaro and ozempic. It’s not even that hard. This sort of price squeezing doesn’t work when the recipe is out there for all to see.
Laughs in Canadian.
(It wasn’t planned, just dumb luck)